Vemurafenib-associated keratoses with genetic heterogeneity of RAS

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Vemurafenib targets advanced melanoma with B-Raf V600E mutations.
• Cutaneous neoplasms, including squamous cell carcinomas and benign keratoses, are common side effects.
• The mitogen-activated protein kinase (MAPK) pathway may be paradoxically activated, contributing to neoplasm development.

Observation:

• Activating RAS mutations are found in vemurafenib-associated squamous cell carcinomas.
• RAS mutations have not been previously reported in benign keratoses.
• This study analyzed RAS genes in verrucous keratoses from a patient with stage IV melanoma on vemurafenib.

Findings:

• No activating RAS mutations were detected in the analyzed verrucous keratoses.
• This finding contrasts with the presence of RAS mutations in squamous cell carcinomas.

Implications:

• The pathogenesis of vemurafenib-associated benign keratoses may not involve RAS mutations.
• Further research is needed to understand the development of these common, quality-of-life-affecting lesions.
• Understanding the genetic basis can inform preventive and therapeutic strategies for vemurafenib-induced skin conditions.